TickerTalks
Browse all tickers →
TickerTalks›$INDV
ININDV

Indivior Pharmaceuticals Inc

$INDV·Drug Manufacturers - Specialty & Generic·Healthcare
——
Mentions · last 7 days
2026-06-19: 1 posts2026-06-20: 0 posts2026-06-21: 1 posts2026-06-22: 4 posts2026-06-23: 1 posts2026-06-24: 8 posts2026-06-25: 7 posts22
X counts updated 3h ago
ININDV
$INDVIndivior Pharmaceuticals Inc
——22 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $INDV.

Drug Manufacturers - Specialty & Generic · Healthcare

Zoetis faces structural uncertainty — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate is whether volume softness is cyclical (pet owners deferring discretionary vet visits) or structural (GLP-1 drugs potentially reducing obesity-related pet conditions long-term).

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+12.8%YTD
+45.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$0.96$0.64+50.0%
Q4 2025Feb 26, 2026$0.82$0.65+26.2%
Q3 2025Oct 30, 2025$0.72$0.38+89.5%
Q2 2025Jul 31, 2025$0.51$0.26+96.2%
Next earningsThu, Jul 30·consensus EPS $0.88

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$RGC$BGM
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport